Question · asked by 1 review
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo: Oral pain
- Population
- Adults with cancer receiving treatment
- Intervention
- Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous
- Comparison
- placebo
- Outcome
- Oral pain
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral pain (mean worst pain, 0 to 10 scale) compared with placebo; GRADE not reported.
What each review found
Include earlier review versionsNo studies found 0 · 0%GRADE not reported 2 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Oral pain (mean worst pain, 0 to 10 scale) · Adults with cancer receiving treatment · BMT/SCT after conditioning for haematological cancers Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral pain (mean worst pain, 0 to 10 scale) compared with placebo; GRADE not reported. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | MD -0.85 [-3.00, 1.30] | 1 study · 42 participants | GRADE not reported |
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Oral pain (mean pain score, 0 to 4 scale) · Adults with cancer receiving treatment · RT to head and neck with cisplatin/fluorouracil Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral pain (mean pain score, 0 to 4 scale) compared with placebo; GRADE not reported. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | MD -0.12 [-0.27, 0.02] | 2 studies · 374 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes | 2017-05 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.